Monday, March 02, 2009

Seroquel Internal E-mails Unsealed

Documents recently unsealed in a U.S. federal court case showed AstraZeneca may have known about the risk of weight gain and diabetes in 2000.

At least one lawyer prosecuting the cases said internal e-mails and other documents showed AstraZeneca officials had evidence of the drug's link to weight gain but used promotions suggesting Seroquel had no effect on weight or could lead to weight loss. Weight gain is a risk factor for development of diabetes.

The drugmaker believes that the Seroquel label has always provided adequate and appropriate information and warnings based on available data.

Source here.